2018
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial
Edelman EJ, Moore BA, Holt SR, Hansen N, Kyriakides TC, Virata M, Brown ST, Justice AC, Bryant KJ, Fiellin DA, Fiellin LE. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. AIDS And Behavior 2018, 23: 211-221. PMID: 30073637, PMCID: PMC6476298, DOI: 10.1007/s10461-018-2241-z.Peer-Reviewed Original ResearchConceptsHIV-positive patientsHeavy drinking daysVACS Index scoreXR-NTXART adherenceDrinking daysIndex scoreUndetectable HIV viral loadCD4 cell countExtended-release naltrexoneDouble-blind placeboHIV viral loadRandomized-controlled trialDrinking outcomesHIV biomarkersSecondary outcomesHIV outcomesPrimary outcomeViral loadAntiretroviral adherenceClinical trialsCell countAlcohol treatmentHIVPatients
2005
Response to hepatitis A vaccine in HIV‐positive patients1
Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV‐positive patients1. Journal Of Viral Hepatitis 2005, 13: 81-86. PMID: 16436125, DOI: 10.1111/j.1365-2893.2005.00658.x.Peer-Reviewed Original ResearchConceptsHepatitis A virusHigher CD4 countsHuman immunodeficiency virusCD4 countHAV vaccineVaccine administrationFemale genderImmune responseMultivariate analysisHepatitis C virus exposureUSPHS/IDSA guidelinesHIV-negative patientsAntiretroviral therapy useChronic liver diseasePredictors of responseLow viral loadIDSA guidelinesVaccination seriesHIV patientsIndependent predictorsTherapy useLiver diseaseOpportunistic infectionsViral loadImmunodeficiency virus